(Total Views: 719)
Posted On: 09/27/2020 5:43:14 PM
Post# of 154646
Old article but informative ..
https://biotuesdays.com/2019/09/17/cytodyn-de...in-a-drug/
Dr. Pourhassan says Leronlimab (PRO140) differentiates itself by a lack of serious side effects, compared with HAART, or any HIV treatment that uses a cocktail of two or more drugs. “While 76% of HIV patients have at least one drug resistance, we have not seen any viral breakthroughs in patients on Leronlimab (PRO140) monotherapy.”
In addition, he points out that while Leronlimab (PRO140) is a weekly, self-administered injection, HAART patients require daily lifetime dosing, with only 35% of patients achieving complete viral load suppression.
CytoDyn has received FDA permission to submit a rolling biologics license application for Leronlimab (PRO140), which the company expects to complete in October 2019, setting the stage for a possible FDA decision by the second quarter of 2020.
https://biotuesdays.com/2019/09/17/cytodyn-de...in-a-drug/
Dr. Pourhassan says Leronlimab (PRO140) differentiates itself by a lack of serious side effects, compared with HAART, or any HIV treatment that uses a cocktail of two or more drugs. “While 76% of HIV patients have at least one drug resistance, we have not seen any viral breakthroughs in patients on Leronlimab (PRO140) monotherapy.”
In addition, he points out that while Leronlimab (PRO140) is a weekly, self-administered injection, HAART patients require daily lifetime dosing, with only 35% of patients achieving complete viral load suppression.
CytoDyn has received FDA permission to submit a rolling biologics license application for Leronlimab (PRO140), which the company expects to complete in October 2019, setting the stage for a possible FDA decision by the second quarter of 2020.
(0)
(0)
